ADAR1 Capital Management, LLC has made a noteworthy move by acquiring additional shares in InMed Pharmaceuticals Inc. This acquisition is part of the firm’s ongoing strategy to increase its holdings in the pharmaceutical sector. The transaction, which took place on October 23, 2026, involved the purchase of four shares at a price of $1.32 each.

Following this transaction, ADAR1 Capital now owns a total of 956,584 shares in InMed Pharmaceuticals. This increase in ownership may signal confidence in InMed's future prospects and could potentially influence market dynamics within the pharmaceutical industry.

Background

ADAR1 Capital Management, LLC is a Texas-based investment firm focused on managing private investment funds. The firm is not publicly traded and does not have a SIC code listed in the SEC filings. Its recent filings include multiple Form 4 submissions, indicating ongoing transactions and changes in share ownership.

What the Filing Says

The SEC filing, accession number 0001940272-26-000028, indicates that ADAR1 Capital Management acquired four shares of InMed Pharmaceuticals on October 23, 2026. The filing states, "The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC." This highlights the direct involvement of the firm's management in the ownership structure.

Impact

This acquisition may affect both ADAR1 Capital and InMed Pharmaceuticals. As a ten percent owner of InMed, ADAR1's actions could be seen as a vote of confidence in the company's future. The pharmaceutical industry, particularly companies like InMed Pharmaceuticals, may feel the ripple effects of such investments as they can impact stock performance and investor sentiment.

What's Next

The filing does not say what happens next. However, continued monitoring of ADAR1's investment strategy and any further acquisitions or divestitures may provide insights into its outlook on InMed Pharmaceuticals and the broader pharmaceutical market.